Clinical trial · Observational
Proteogenomics for Follicular Cell-derived Thyroid Cancer: Development of a Classification and Prognosis Prediction Model
Integrative Multi-Omics Refines the Molecular Subtypes of Thyroid Cancers and Enhances Cancer-Progression Prediction
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to refine the molecular classification of thyroid cancer (TC) using a multi-omics approach. By identifying a novel gene set and applying decision-tree modeling, the study seeks to improve diagnostic accuracy and predict tumor progression in BRAFV600E-like and RAS-like TC subtypes. Protein biomarkers were validated via immunohistochemistry (IHC), with findings confirmed across external datasets.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Thyroid cancer
- description
- All patients diagnosed with thyroid cancer who underwent thyroidectomy at Seoul National University Hospital
Primary outcomes (1)
- measure
- Classification Accuracy of Gene-Based Model
- timeFrame
- 1 year
- description
- The accuracy of the decision-tree model using specific gene set to classify thyroid cancer into BRAFV600E-like, RAS-like, and NT (normal thyroid) -like subtypes. Model performance will be evaluated using accuracy, sensitivity, specificity, and Cohen's kappa.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a confirmed clinical diagnosis of thyroid cancer * Availability of surgically resected thyroid tissue suitable for omics analysis Exclusion Criteria: \- Patients who have received chemotherapy for other malignancies
References
Publications (0)
Data not yet available